Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Nalbuphine · Nalbuphine Hydrochloride, Nubain

Small molecule · Agonist of kappa opioid receptor (OPRK1) and mu opioid receptor (OPRM1) · developed by Ph Health

Approved FDA, May 1979
1 Registered trials

What is Nalbuphine?

Nalbuphine is a synthetic mixed opioid agonist-antagonist that binds kappa receptors in the central nervous system to inhibit pain-mediating neurotransmitter release and exerts inhibitory effects on the spinothalamic tract. It antagonizes mu receptors, potentially producing less respiratory depression than other opioids. It is studied for uremic pruritus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Nalbuphine Hydrochloride, Nubain
Drug type
Small molecule
Targets
kappa opioid receptor (OPRK1), mu opioid receptor (OPRM1)
Mechanism
Agonist of kappa opioid receptor (OPRK1) and mu opioid receptor (OPRM1)
Pathways
nociceptive signaling, neurotransmitter release
Therapy area
Neurology
Developer
Ph Health
In trials of
DVA
FDA status
Approved as Nalbuphine Hydrochloride, Nubain (May 15, 1979), NDA018024
UNII
L2T84IQI2K

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02373215 Phase 1 Uremic Pruritus Completed DVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Uremic Pruritus

Other drugs acting on OPRK1 / OPRM1

Methadone FDA approved Morphine FDA approved Naloxone FDA approved Naltrexone FDA approved Oxycodone FDA approved PF614 Phase 3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.